Endoscopic treatment
Summary
General remarks
Indications for endoscopic resection
Diagnosis by histopathology of the resected tissue specimens
Treatment of lesions not amenable to endoscopic resection
Superiority of en bloc resection
Complications
CQ18: is additional treatment recommended in cases detected to have pT1a-MM lesion following endoscopic treatment for superficial esophageal cancer?
Recommendation statement
Explanatory note
Surgical treatment
Surgery for cervical esophageal carcinoma
Summary
General remarks
Surgery for thoracic esophageal carcinoma
Summary
General remarks
Surgery for carcinoma of the esophagogastric junction (abdominal esophageal carcinoma)
Summary
General remarks
Perioperative management and clinical path
Summary
General remarks
Chemotherapy for unresectable advanced/recurrent esophageal cancer
Summary
General remarks
Drugs and drug combinations that have been shown to be effective as the first-line therapy
Regimen | N | Response rate (%) | Progression-free survival (month) | Median survival (month) |
---|---|---|---|---|
Cisplatin 100 mg/m2 on day 1 5-FU 1000 mg/m2/day on days 1–5/every 3 weeks | SCC 44 | 35 | 6.2 | 7.6 |
Cisplatin 70 mg/m2 on day 1 5-FU 700 mg/m2/day on days 1–5/every 3 weeks | SCC 39 | 35.9 | Patients with response 3.5 | Patients with response 9.5 |
Nedaplatin 90 mg/m2 on day 1 5-FU 800 mg/m2/day on days 1–5/every 4 weeks | SCC 42 | 39.5 | 2.5 | 8.8 |
Doxorubicin 30 mg/m2/day on day 1 5-FU 700 mg/m2/day on days 1–5 Cisplatin 14 mg/m2/day on days 1–5/every 4 weeks | SCC 41 | 43.9 | 5.0 | 10.1 |
Docetaxel 30 to 40 mg/m2/day on days 1 and 15 5-FU 800 mg/m2/day on days 1–5 Cisplatin 80 mg/m2 on day 1/every 4 weeks | SCC 55 | 62 | 5.8 | 11.1 |
Drugs and combination therapies shown to be effective as the second-line therapy
Regimen | N | Response rate (%) | Progression-free survival (month) | Median survival (month) |
---|---|---|---|---|
Docetaxel 70 mg/m2 every 3 weeks | SCC 46a AC 3 Others 2 | 20 | 2.3 | 8.1 |
Paclitaxel 100 mg/m2 on days 1, 8, 15, 22, 29, and 35/every 7 weeks | SCC 52 | 44.2 | 3.9 | 10.4 |
Docetaxel 30 mg/m2/day on day 1 Nedaplatin 50 mg/m2 on day 1/every 2 weeks | SCC 48 | 27.1 | 3.1 | 5.9 |
Nivolumab 3 mg/kg/every 2 weeks | SCC 64 | 17 | 1.5 | 10.8 |
Drugs and combination therapies shown to be effective as the third-line therapy
Radiotherapy
Summary
General remarks
Multidisciplinary treatment
Preoperative/postoperative adjuvant therapy
Summary
General remarks
Chemoradiotherapy
Summary
Study name | Histological type studied | Regimen | Radiation dose (Gy) | Complete response rate (%) | Survival (%) |
---|---|---|---|---|---|
JCOG9708 | cStage Ib SCC | Cisplatin 70 mg/m2 on days 1 and 36 5-FU 700 mg/m2 on days 1–4 and 36–39 | 60 | 87.5 | 4-year survival 80.5 |
RTOG85-01 | cStage I, II, III SCC, AC | Radiotherapy alone | 64 | NA | 5-year survival 0 |
Cisplatin 75 mg/m2 on days 1 and 29 5-FU 1000 mg/m2 on days 1–4 and 29–32 | 50 | NA | 5-year survival 27 | ||
RTOG94-05 | cStage I, II, III SCC, AC | Cisplatin 75 mg/m2 on days 1 and 29 5-FU 1000 mg/m2 on days 1–4 and 29–32 | 50.4 | NA | 2-year survival 40 |
Cisplatin 75 mg/m2 on days 1 and 29 5-FU 1000 mg/m2 on days 1–4 and 29–32 | 64.8 | NA | 2-year survival 31 | ||
JCOG9906 | cStage II, III SCC | Cisplatin 40 mg/m2 on days 1, 8, 36 and 43 5-FU 400 mg/m2 on days 1–5, 8–12, 36–40, and 43–47 | 60 | 62.2 | 3-year survival 44.7 |
mRTOG | cStage II, III SCC | Cisplatin 75 mg/m2 on days 1 and 29 5-FU 1000 mg/m2 on days 1–4 and 29–32 | 50.4 | 70.6 | 3-year survival 63.8 |
JCOG9516 | Unresectable local SCC | Cisplatin 70 mg/m2 on days 1 and 36 5-FU 700 mg/m2 on days 1–4 and 36–39 | 60 | 15 | 2-year survival 31.5 |
JCOG0303 | Unresectable local SCC | Cisplatin 70 mg/m2 on days 1 and 29 5-FU 700 mg/m2 on days 1–4 and 29–32 | 60 | 0 | 3-year survival 25.9 |
Cisplatin 4 mg/m2/5 doses weekly for 6 weeks 5-FU 200 mg/m2/5 doses weekly for 6 weeks | 60 | 1.4 | 3-year survival 25.7 | ||
KROSG0101/JROSG021 | cStage II, IVA local SCC | Cisplatin 70 mg/m2 on days 1 and 29 5-FU 700 mg/m2 on days 1–5 and 29–33 | 60 | NA | 2-year survival 46 |
Cisplatin 7 mg/m2 on days 1–5, 8–12, 29–33 and 36–40 5-FU 250 mg/m2 on days 1–14 and 29–42 | 60 | NA | 2-year survival 44 | ||
KDOG0501 | Unresectable local SCC | Cisplatin 40 mg/m2 on days 1, 15, 29, and 43 5-FU 400 mg/m2 on days 1–5, 15–19, 29–33, and 43-47 Docetaxel 20–40 mg/m2 on days 1, 15, 29, and 43 | 61.2 | 42.1 | 1-year survival 63.2 |